Furue H, Mugitani H, Hirota F, Suminaga M
Dept. of Internal Medicine, Teikyo University, School of Medicine.
Gan To Kagaku Ryoho. 1988 Apr;15(4 Pt 2-1):797-803.
Among interferon (IFN)-alpha, beta, gamma, there are no differences in its clinical effects and toxicities. As to IFN-alpha, there are leukocyte IFN, lymphoblastoid IFN, recombinant IFN-alpha 2a, 2b, and 2c. Now we have largely completed the process of surveying for anticancer effects over the broad range of malignancies. However, the adequate method of administration, route, dose, and interval are not yet fully established. Dose response remains unanswered question with some contradictory results in in vitro and clinical reports. The actual mechanism responsible for its anticancer activity is still not known. The question of what variables to monitor in assessing adequate dosages of IFN remains unsolved. Several trials have examined the possibility of combining IFN with other treatment modalities including anticancer agents, BRMs, radiation, etc. It should be acknowledged that we remain at a very early stage in our understanding of IFN. In future, IFN may play an even larger role when used in an adjuvant setting or as part of multimodality cancer treatment.
在干扰素（IFN）-α、β、γ之间，其临床效果和毒性并无差异。至于IFN-α，有白细胞干扰素、淋巴母细胞样干扰素、重组IFN-α 2a、2b和2c。目前，我们已基本完成了在广泛的恶性肿瘤范围内考察抗癌效果的过程。然而，合适的给药方法、途径、剂量和间隔尚未完全确立。剂量反应仍是一个未解决的问题，体外和临床报告中有一些相互矛盾的结果。其抗癌活性的实际机制仍然未知。在评估IFN的合适剂量时应监测哪些变量的问题仍未解决。几项试验研究了将IFN与其他治疗方式联合使用的可能性，包括抗癌药物、生物反应调节剂、放疗等。应该认识到，我们对IFN的理解仍处于非常早期的阶段。未来，IFN在辅助治疗或作为多模式癌症治疗的一部分使用时可能会发挥更大的作用。
